source
- BMS reports Phase 3 success for RYZ101 in GEP-NET trialBristol Myers Squibb said its radiopharmaceutical candidate RYZ101 met the primary endpoint in a late‑stage Phase 3 study. The drug was acquired in BMS's $4.1 billion purchase of RayzeBio, complete…
- BMS reports phase 3 successes in IPF drug and neuroendocrine tumor radiotherapyBristol Myers Squibb announced that two of its phase 3 trials have met primary endpoints, marking important milestones as the company seeks growth beyond its patent expirations. The Aloft-IPF stud…